Retatrutide cut sleep apnea events by up to 24 per hour over placebo

The trials, named TRIUMPH-1-OSA and TRIUMPH-2-OSA, were both double-blind, randomized, and placebo-controlled ¹. Each trial enrolled adults with moderate-to-severe obstructive sleep apnea, a condition in which the throat narrows or closes during sleep and breathing pauses. Participants also had a body-mass index of at least 27 ¹. In TRIUMPH-1-OSA, 243 people without type 2 diabetes were randomly assigned to one of three weekly retatrutide doses, 4 mg, 9 mg, or 12 mg, or to placebo. In TRIUMPH-2-OSA, 448 people with type 2 diabetes were assigned in the same way ¹.

The main outcome was the apnea-hypopnea index, or AHI. AHI is the average number of times per hour that a person stops breathing or breathes so shallowly that oxygen dips during sleep ¹. The researchers measured how much the AHI changed from the start of the trial to week 80. At the start, the average AHI was 58.6 events per hour in the first trial and 55.9 events per hour in the second. The average body weight was 119.6 kg and 115.9 kg ¹.

In TRIUMPH-1-OSA, the mean AHI change at 80 weeks was -22.9 events per hour with 4 mg, -34.3 with 9 mg, and -31.7 with 12 mg. Placebo was linked to -9.9 events per hour ¹. The 9 mg dose therefore showed a difference of -24.4 events per hour versus placebo. The 95% confidence interval for that difference was -34.1 to -14.7 events per hour. A confidence interval is the range that likely contains the true effect. The 12 mg dose showed a difference of -21.9 events per hour versus placebo, with a confidence interval of -32.2 to -11.5 ¹. Put plainly, people in the 9 mg group had about 24 fewer breathing pauses per hour than people in the placebo group.

In TRIUMPH-2-OSA, the mean changes with retatrutide were -19.2 events per hour with 4 mg, -24.7 with 9 mg, and -25.4 with 12 mg ¹. The abstract does not provide the placebo change for this trial, so the direct comparison is incomplete. The pattern is the same: the higher doses produced larger reductions, with the 9 and 12 mg results close together.

Sleep apnea often tracks body weight, and retatrutide has produced large mean weight loss in earlier trials. The Phase 2 obesity trial reported mean weight loss of 24.2% at the 12 mg weekly dose over 48 weeks ². A separate systematic review in adults without diabetes placed the placebo-subtracted loss around 22% ³. In the TRANSCEND-T2D-1 Phase 3 trial in type 2 diabetes, the same 12 mg dose led to weight loss of about 15.3% over 40 weeks ⁴. These numbers are among the largest seen for medicines that act on the GLP-1 receptor.

The sleep apnea trials do not report weight change at 80 weeks in the abstract, so the role of weight change in the AHI result is not stated ¹. The baseline body weight in both trials was around 116 to 120 kg, and body-mass index was at least 27, so these were people with substantial overweight or obesity ¹.

Retatrutide is not a single-hormone medicine. It combines three signals: GLP-1, which lowers appetite and slows stomach emptying; GIP, which supports insulin release after meals; and glucagon, which raises resting energy expenditure ⁴. In simple terms, the triple signal is designed to reduce how much fuel comes in and increase how much fuel is burned ⁵.

This triple mechanism is the background for the sleep apnea finding. The trial itself did not separate weight loss from any direct effect on the airway ¹. The abstract reports the change in AHI, but it does not say how much of that change came from weight loss versus an independent effect.

The sleep apnea abstract does not include a safety summary ¹. Earlier Phase 2 trials found that stomach side effects were the most common: nausea, vomiting, diarrhea, and constipation, mostly mild to moderate and more common at higher doses ⁶. A network meta-analysis ranked retatrutide's adverse-event burden above tirzepatide's, with the difference driven by gastrointestinal events ⁷.

We do not know from ¹ whether the sleep apnea trials found the same pattern, because the abstract stops at efficacy results. The medicine remains investigational and not approved in any country ⁸.

The abstract does not report weight change at 80 weeks, so we cannot tell how much of the AHI drop came from weight loss alone. We do not have the placebo comparison for TRIUMPH-2-OSA, so the size of the benefit in people with type 2 diabetes is less certain. We also do not have safety data from the 80-week sleep apnea trials in this abstract. Long-term durability beyond 80 weeks, and whether the sleep apnea benefit continues after treatment stops, are open questions.